— Three Antimicrobial Susceptibility Tests Cleared by FDA for Use with NUZYRA —

— Launches  KEYSTONETM Surveillance Program to Monitor Omadacycline Susceptibility —
BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the commercial availability of NUZYRA™ (omadacycline) in the United States.  NUZYRA, a modernized tetracycline, is a once-daily intravenous and oral antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (…

READ FULL TEXT